- POSITIVE
Quarterly Revenue Oxygenta Pharma Jun-2026 Quarterly Revenue is Rs 37 Cr which is growth of 141.9% YoY.
- POSITIVE
Quarterly Net Profit Oxygenta Pharma Jun-2026 Quarterly Net Profit is Rs -2 Cr which is growth of 65.6% YoY.
Oxygenta Pharma quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents
Oxygenta Pharma quarterly results: revenue, profit, and P&L – 13 quarter history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
| Indicator | Graph | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37 | 49.8 | 33.9 | 14.3 | 15.3 | 49.5 | 33.7 | 14.8 | 12.6 | 10.6 | 9.2 | 13.1 | 6.9 | ||
Operating Exp. | 36.5 | 49.5 | 38 | 18.9 | 22 | 51.2 | 37.6 | 16.2 | 14.4 | 12.2 | 11.6 | 15.1 | 10.5 | |
Operating Profit | 0.6 | 0.1 | -4.1 | -4.6 | -6.8 | -1.7 | -4.4 | -2.2 | -1.8 | -1.6 | -2.5 | -2 | -3.6 | |
Operating Profit Margin % | 1.48% | 0.23% | -12.01% | -31.99% | -45.12% | -3.40% | -13.12% | -15.51% | -14.13% | -15.30% | -27.00% | -15.11% | -52.97% | |
Depr. | 0.6 | -0.2 | 0.9 | 0.9 | 0.9 | -0.2 | 0.7 | 0.7 | 0.7 | 0.6 | 0.7 | 0.8 | 0.5 | |
Interest | 2.5 | 1.8 | 1.4 | 1 | 0.6 | 2.1 | 0.4 | 0.7 | 0.4 | 0.6 | 0.4 | 0.3 | 0.3 | |
Profit Before Tax | -2.5 | -1.3 | -6.3 | -6.4 | -8.2 | -3.8 | -5 | -2.8 | -2.8 | -2.6 | -3.6 | -3.2 | -4.6 | |
Tax | -0.4 | 0.4 | -1.5 | -1.5 | -2 | -1.7 | -1 | 0.1 | -1.5 | -10.6 | 0.2 | -0 | ||
Net Profit | -2.1 | -1.7 | -4.8 | -4.9 | -6.1 | -2.2 | -3.9 | -2.9 | -1.4 | 8 | -3.8 | -3.2 | -4.6 | |
EPS Adj. latest | -0.6 | -0.5 | -1.3 | -1.3 | -1.7 | -0.6 | -1.1 | -0.8 | -0.4 | 2.2 | -1 | -0.9 | -1.2 | |
Net profit TTM | -13.6 | -17.6 | -18 | -17.1 | -15 | -10.3 | -0.1 | 0 | -0.3 | -3.5 | -15.8 | -15.3 | -14.4 | |
Basic EPS TTM | -3.7 | -4.8 | -4.9 | -4.6 | -4.1 | -2.8 | -0 | 0 | -0.1 | -1 | -4.7 | -4.6 | -4.3 | |
Results PDF | ||||||||||||||
Result Notes |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Oxygenta Pharma competitor comparison and performance snapshot within industry
Oxygenta Pharma annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- POSITIVE
Annual Revenue Oxygenta Pharma Mar-2026 Annual Revenue is Rs 113 Cr which is growth of 2.4% YoY.
- NEGATIVE
Annual Net Profit Oxygenta Pharma Mar-2026 Annual Net Profit is Rs -18 Cr which is growth of -81.5% YoY.
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
2.4%
2Y CAGR
68.9%
3Y CAGR
54%
5Y CAGR
16.8%
7Y CAGR
27.4%
10Y CAGR
24.8%
Total Revenue Annual growth is lower than historical averages.
Operating Exp. Ann.
1Y CHG
7.5%
2Y CAGR
61.3%
3Y CAGR
49.9%
5Y CAGR
21.6%
7Y CAGR
28.2%
10Y CAGR
22.7%
Operating Expenses Annual Cr growth is lower than historical averages.
Oxygenta Pharma balance sheet as of Mar 2026: assets, liabilities, reserves, and borrowings – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEGATIVE
Total Shareholders Fund Oxygenta Pharma Mar-2026 Total Shareholders Fund is Rs -43 Cr which is growth of -70.6% YoY.
- POSITIVE
Total Assets Oxygenta Pharma Mar-2026 Total Assets is Rs 120 Cr which is growth of 43.5% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | Mar '16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
- | - | -42.7 | -25 | -20.1 | -46.2 | -34.6 | -38 | -41 | -35.2 | -31.9 | -27.4 | -21.6 | ||
Minority Interest Liability Ann. | - | - | - | - | - | - | - | - | - | - | - | - | - | |
2.6% | 7% | 76.3 | 22.6 | 49.6 | 70.7 | 57.8 | 54.4 | 43.7 | 39.6 | 29.2 | 29.2 | 20.6 | ||
42.4% | 37.5% | 86.1 | 85.9 | 33.7 | 29.8 | 8 | 17.5 | 15.9 | 16.7 | 19.7 | 17.2 | 20.8 | ||
Total Capital Plus Liabilities Ann. | 30.1% | 28.7% | 119.7 | 83.4 | 63.2 | 54.3 | 31.2 | 33.9 | 18.6 | 21.2 | 17 | 19.1 | 19.8 | |
19.5% | 22.9% | 47.6 | 39.9 | 29.4 | 27.9 | 20.3 | 17 | 11.4 | 11.9 | 12.4 | 12.9 | 12.9 | ||
32.6% | 30.7% | 68.3 | 52.5 | 39.1 | 29.3 | 21.6 | 17.9 | 11.9 | 12.4 | 12.7 | 13.2 | 14.4 | ||
27.2% | 26.4% | 51.4 | 30.9 | 24.1 | 25 | 9.6 | 15.9 | 6.8 | 8.8 | 4.2 | 5.8 | 5.4 | ||
Total Assets Ann. | 30.1% | 28.7% | 119.7 | 83.4 | 63.2 | 54.3 | 31.2 | 33.9 | 18.6 | 21.2 | 17 | 19.1 | 19.8 | |
Contingent Liabilities plus Commitments Ann. | 41.5% | 23.2% | 3.4 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 2 | 1.6 | ||||
Bonus Equity Share Capital Ann. | - | - | ||||||||||||
Non Current Investments Unquoted Book Value Ann. | 71% | - | 0.5 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |||||
Current Investments Unquoted Book Value Ann. | - | - |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Assets Ann.
1Y CHG
43.5%
2Y CAGR
37.6%
3Y CAGR
30.1%
5Y CAGR
28.7%
7Y CAGR
28.1%
10Y CAGR
19.7%
Total Assets Annual growth is higher than historical averages.
Total Current Liabilities Ann.
1Y CHG
0.2%
2Y CAGR
59.8%
3Y CAGR
42.4%
5Y CAGR
37.5%
7Y CAGR
26.4%
10Y CAGR
15.3%
Total Current Liabilities Annual Cr growth is lower than historical averages.
Oxygenta Pharma ROE, ROCE, book value, and debt-to-equity ratio as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEGATIVE
Book Value Per Share Oxygenta Pharma Mar-2026 Book Value Per Share is -12 Rs which is growth of -70.6% YoY.
- NEUTRAL
ROE Oxygenta Pharma Mar-2026 ROE is 0% which is growth of 0% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | Mar '16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BVSH Ann. | - | - | -11.5 | -6.8 | -6 | -32.5 | -24.4 | -37.3 | -40.1 | -34.5 | -31.3 | -26.8 | -21.1 | |
RoA Ann. % | - | - | -14.68% | -11.60% | -5.50% | -21.32% | -1.95% | 8.65% | -31.08% | -15.37% | -26.69% | -30.46% | -27.82% | |
ROE Ann. % | - | - | -7.70% | |||||||||||
ROCE Ann. % | - | - | -51.77% | 391.43% | -41.74% | -37.43% | -0.47% | 16.72% | -318.40% | -61.96% | 132.68% | -280.18% | 508.31% | |
Total Debt to Total Equity Ann. | - | - | -2.6 | -2.5 | -2.8 | -1.5 | -1.5 | -1.3 | -0.6 | -0.6 | -0.6 | -0.7 | -0.8 |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Current Ratio Ann.
1Y CHG
50%
2Y CAGR
-7.4%
3Y CAGR
-9.1%
5Y CAGR
-7.8%
7Y CAGR
2.6%
10Y CAGR
7.2%
Current Ratio Annual growth is higher than historical averages.
Oxygenta Pharma cash flow: net, operating, investing, and financing flows as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEGATIVE
Cash From Operating Activity Oxygenta Pharma Mar-2026 Cash From Operating Activity is Rs -28 Cr which is growth of -1166.3% YoY.
- POSITIVE
Net Cash Flow Oxygenta Pharma Mar-2026 Net Cash Flow is Rs 0 Cr which is growth of 1896.7% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | Mar '16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
- | - | -27.8 | 2.6 | -13.1 | -1.6 | -1.7 | -1.6 | -6.6 | -7.8 | 1.3 | 0.5 | 0.9 | ||
Cash from Investing Act. Ann. | - | - | -14.4 | -11.3 | -4.1 | -9.6 | -4.9 | -6.7 | -0.5 | -0.6 | -0.4 | -0.9 | -2.1 | |
Cash from Financing Act. Ann. | 56.1% | 37.4% | 42.6 | 8.7 | 17.1 | 11.2 | 6.3 | 8.7 | 3.2 | 8.4 | -0.9 | 0.4 | 1.2 | |
- | 5.9% | 0.4 | 0 | -0 | -0.1 | -0.3 | 0.3 | -3.9 | 0 | -0 | 0 | -0.1 |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Cash from Financing Act. Ann.
1Y CHG
389.7%
2Y CAGR
57.8%
3Y CAGR
56.1%
5Y CAGR
37.4%
7Y CAGR
26.1%
10Y CAGR
42.9%
Cash from Financing Annual Activity growth is higher than historical averages.
